Feasibility and pilot efficacy results from the multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) randomized controlled trial

Journal of Clinical Psychiatry

Volumn 73, Issue 7, 2012, Pages 1016-1022

  Keefe, Richard S E ^a   Vinogradov, Sophia ^b   Medalia, Alice ^c   Buckley, Peter F ^d   Caroff, Stanley N ^e   D'Souza, Deepak C ^f   Harvey, Phillip D ^g   Graham, Karen A ^h   Hamer, Robert M ^h   Marder, Stephen M ^i,j   Miller, Del D ^k   Olson, Stephen J ^l   Patel, Jayendra K ^m   Velligan, Dawn ⁿ   Walker, Trina M ^a   Haim, Adam J ^o   Scott Stroup, T ^c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Department of Psychiatry Columbia University College of Physicians and Surgeons ^*  (United States)

^d MEDICAL COLLEGE OF GEORGIA   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^h IL   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j Geriatric Research Education   (United States)

^k UNIVERSITY OF IOWA   (United States)

^l UNIVERSITY OF MINNESOTA   (United States)

^m UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

ⁿ Mays Cancer Center at UT Health San Antonio   (United States)

^o NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BEHAVIOR THERAPY; COGNITIVE REMEDIATION; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; GAME; GROUP THERAPY; HUMAN; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PILOT STUDY; POSIT BRAIN FITNESS AUDITORY TRAINING PROGRAM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA;

EID: 84864405529     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.11m07100     Document Type: Article

References (38)

1. Keefe RSE, Eesley CE, Poe MP. Defining a cognitive function decrement in schizophrenia. Biol Psychiatry. 2005;57(6):688-691. doi:10.1016/j.biopsych.205. 01.03 PubMed (Pubitemid 40409709)
2. Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology. 1998;12(3):426-445. doi:10.1037/0894-4105.12.3.426 PubMed (Pubitemid 28323862)
3. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996;153(3):321-330. PubMed (Pubitemid 26074706)
4. Green MF, Kern RS, Braff DL, et al. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr Bull. 2000;26(1):119-136. PubMed (Pubitemid 30317696)
5. Keefe RSE, Bilder RM, Davis SM, et al Neurocognitive Working Group. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry. 2007;64(6):633-647. doi:10.101/archpsyc.64.6.63 PubMed (Pubitemid 46878665)
6. Davidson M, Galderisi S, Weiser M, et al. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry. 2009;166(6):675-682. doi:10.176/api.ajp.208.08060806 PubMed
7. Buchanan RW, Keefe RS, Umbricht D, et al. The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later? Schizophr Bull. 2011;37(6):1209-1217. doi:10.1093/schbul/sbq038 PubMed
8. Kane JM, D'Souza DC, Patkar AA, et al. Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study. J Clin Psychiatry. 2010;71(11):1475- 1481. doi:10.408/JCP.09m05950gry PubMed
9. Goff D, Hill M, Barch D. The treatment of cognitive impairment in schizophrenia. Pharmacol Biochem Behav. 2011;99(2):245-253. doi:10.1016/j.pb. 2010.1.09 PubMed
10. Keefe RSE, Vinogradov S, Medalia A, et al. Report from the working group conference on multisite trial design for cognitive remediation in schizophrenia. Schizophr Bull. 2011;37(5):1057-1065. doi:10.1093/schbul/sbq010 PubMed
11. Wykes T. Cognitive remediation therapy needs funding. Nature. 2010;468(7321):165-166. doi:10.1038/468165a PubMed
12. McGurk SR, Mueser KT, Feldman K, et al. Cognitive training for supported employment: 2-3 year outcomes of a randomized controlled trial. Am J Psychiatry. 2007a;164(3):437-441. doi:10.176/api.ajp.164.3.437 PubMed (Pubitemid 46513157)
13. McGurk SR, Twamley EW, Sitzer DI, et al. A meta-analysis of cognitive remediation in schizophrenia. Am J Psychiatry. 2007b;164(12):1791-1802. doi:10.176/api.ajp.207.07060906 PubMed (Pubitemid 351739231)
14. Wykes T, Reeder C, Corner J, et al. The effects of neurocognitive remediation on executive processing in patients with schizophrenia. Schizophr Bull. 1999;25(2):291-307. PubMed (Pubitemid 29272506)
15. Fisher M, Holland C, Merzenich MM, et al. Using neuroplasticity-based auditory training to improve verbal memory in schizophrenia. Am J Psychiatry. 2009;166(7):805-811. doi:10.176/api.ajp.209.08050757 PubMed
16. Fisher M, Holland C, Subramaniam K, et al. Neuroplasticity-based cognitive training in schizophrenia: an interim report on the effects 6 months later. Schizophr Bull. 2010;36(4):869-879. doi:10.1093/schbul/sbn170 PubMed
17. Wykes T, Huddy V, Cellard C, et al. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am J Psychiatry. 2011;168(5):472-485. doi:10.176/api.ajp.2010.106085 PubMed
18. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276. PubMed (Pubitemid 18039085)
19. Nuechterlein KH, Green MF, Kern RS, et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008;165(2):203-213. doi:10.176/api.ajp.207.0701042 PubMed (Pubitemid 351704520)
20. Wilkinson GS. Wide Range Achievement Test 3 Administration Manual. Wilmington, DE: Wide Range Inc; 1993.
21. Mahncke HW, Bronstone A, Merzenich MM. Brain plasticity and functional losses in the aged: scientific bases for a novel intervention. Prog Brain Res. 2006;157:81-109. doi:10.1016/S079-6123(06)5706-2 PubMed (Pubitemid 44550260)
22. Medalia A, Revheim N. In: Herlands T, ed. Cognitive Remediation for Psychological Disorders: Therapist Guide. New York, NY: Oxford University Press; 2009.
23. Ganguli R. Behavioral therapy for weight loss in patients with schizophrenia. J Clin Psychiatry. 2007;68(suppl 4):19-25. PubMed (Pubitemid 46766508)
24. Patterson TL, Goldman S, McKibbin CL, et al. UCSD Performance-Based Skills Assessment: development of a new measure of everyday functioning for severely mentally ill adults. Schizophr Bull. 2001;27(2):235-245. PubMed (Pubitemid 33644299)
25. Green MF, Schooler NR, Kern RS, et al. Evaluation of functionally meaningful measures for clinical trials of cognition enhancement in schizophrenia. Am J Psychiatry. 2011;168(4):400-407. doi:10.176/api.ajp.2010. 1030414 PubMed
26. Ventura J, Reise SP, Keefe RS, et al. The Cognitive Assessment Interview (CAI): development and validation of an empirically derived, brief interview-based measure of cognition. Schizophr Res. 2010;121(1-3):24-31. doi:10.1016/j.schres.2010.04.016 PubMed
27. Kay SR, Opler LA, Lindenmayer JP. The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br J Psychiatry suppl. 1989;7(7):59-67. PubMed
28. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health; 1976: 218-222.
29. Schneider LC, Struening EL. SLOF: a behavioral rating scale for assessing the mentally ill. Soc Work Res Abstr. 1983;19(3):9-21. PubMed
30. Rosenberg M. Society and the Adolescent Self-Image. Princeton, NJ: Princeton University Press; 1965.
31. Choi J, Mogami T, Medalia A. Intrinsic motivation inventory: an adapted measure for schizophrenia research. Schizophr Bull. 2010;36(5):966-976. doi:10.1093/schbul/sbp030 PubMed
32. Choi J, Fiszdon JM, Medalia A. Expectancy-value theory in persistence of learning effects in schizophrenia: role of task value and perceived competency. Schizophr Bull. 2010;36(5):957-965. doi:10.1093/schbul/sbq078 PubMed
33. Tarrier N, Wykes T. Is there evidence that cognitive behaviour therapy is an effective treatment for schizophrenia? a cautious or cautionary tale? Behav Res Ther. 2004;42(12):1377-1401. doi:10.1016/j.brat.204.06.020 PubMed (Pubitemid 39410355)
34. Keefe RSE, Fox KH, Harvey PD, et al. Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial. Schizophr Res. 2011;125(2-3):161-168. doi:10.1016/j.schres.2010.09.015 PubMed
35. Keefe RS, Buchanan RW, Marder SR, et al. Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? [published online ahead of print November 22, 2011]. Schizophr Bull. PubMed
36. Medalia A, Richardson R. What predicts a good response to cognitive remediation interventions? Schizophr Bull. 2005;31(4):942-953. doi:10.1093/schbul/sbi045 PubMed (Pubitemid 41437789)
37. Choi J, Medalia A. Factors associated with a positive response to cognitive remediation in a community psychiatric sample. Psychiatr Serv. 2005;56(5):602-604. doi:10.176/api.ps.56.5.602 PubMed (Pubitemid 40586846)
38. Twamley EW, Savla GN, Zurhellen CH, et al. Development and pilot testing of a novel compensatory cognitive training intervention for people with psychosis. Am J Psychiatr Rehabil. 2008;11(2):144-163. doi:10.1080/ 1548760801963678 PubMed (Pubitemid 351507794)